Centres of Excellence
Our mission is to accelerate patient access to evidence-based innovation in mental health. An important part of this is understanding how potential new therapies can integrate effectively into health systems, and have a positive impact on people’s lives.
Our Centres of Excellence help us to do exactly this.
Formed in partnership with leading academic, research and clinical institutions, our Centres of Excellence are hubs that combine scientific rigour and real-world insights to deliver world-class research and innovation that will help to shape new models of mental health care.
Centre of Excellence in Baltimore, US
Our Centre of Excellence in Baltimore, launched in January 2021 in partnership with Sheppard Pratt, is modelling the “clinic of the future”, showcasing the best thinking in science, therapy, technology and design. Working as a research facility and innovation lab, it is generating evidence to shape therapy models in mental health care, train and certify therapists, conduct clinical trials including proof-of-concept studies, and prototype digital solutions to improve patient experience.
The Centre for Mental Health Research and Innovation in London, UK
The Centre for Mental Health Research and Innovation was launched in March 2022 in partnership with South London and Maudsley NHS Foundation Trust (SLaM), the largest mental health trust in the UK National Health Service (NHS) and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London.
The Centre is working to accelerate research of emerging psychedelic therapies, support therapist training and certification, evaluate real-world evidence, and prototype digital technologies to enable personalised, predictive and preventative care models.
The Centre is currently located at Maudsley Hospital, London, while state-of-the-art facilities are built within a 200 acre woodland at Bethlem Royal Hospital, London. This dedicated and purpose-built space for late-stage clinical trials will be managed by leading clinical investigators with extensive experience in conducting psychedelic clinical trials, and will provide access to COMP360 psilocybin therapy to an estimated 650-700 patients over a five-year term.